Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy VERA Stock  Free VERA Stock Alerts

Vera Therapeutics (VERA) Financials

Vera Therapeutics logo
$19.64 +0.01 (+0.05%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$19.45 -0.19 (-0.97%)
As of 05/23/2025 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Vera Therapeutics

Annual Income Statements for Vera Therapeutics

This table shows Vera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders		 -152 -96 -89 -33 -53
Consolidated Net Income / (Loss)		 -152 -96 -89 -33 -53
Net Income / (Loss) Continuing Operations		 -152 -96 -89 -33 -53
Total Pre-Tax Income 		-152 -96 -89 -33 -53
Total Operating Income		 -167 -102 -91 -34 -52
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 167 102 91 34 52
Selling, General & Admin Expense		 41 24 22 12 4.04
Research & Development Expense		 126 78 69 22 45
Total Other Income / (Expense), net		 15 6.02 1.85 1.79 -1.17
Interest Expense		 7.63 3.79 0.99 0.02 0.17
Interest & Investment Income		 21 7.98 1.75 0.02 0.01
Other Income / (Expense), net		 1.94 1.83 1.09 1.80 -1.01
Income Tax Expense		 0.00 0.00 0.00 0.00 -0.00
Basic Earnings per Share		 ($2.75) ($2.25) ($3.35) ($2.43) ($166.93)
Weighted Average Basic Shares Outstanding		 55.33M 42.71M 26.57M 13.44M 319.96K
Diluted Earnings per Share		 ($2.75) ($2.25) ($3.35) ($2.43) ($166.93)
Weighted Average Diluted Shares Outstanding		 55.33M 42.71M 26.57M 13.44M 319.96K
Weighted Average Basic & Diluted Shares Outstanding		 0.00 54.45M 44.26M 13.44M 319.96K

Quarterly Income Statements for Vera Therapeutics

This table shows Vera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -52 -43 -47 -34 -28 -26 -20 -20 -30 -32 -25
Consolidated Net Income / (Loss)		 -52 -43 -47 -34 -28 -26 -20 -20 -30 -32 -25
Net Income / (Loss) Continuing Operations		 -52 -43 -47 -34 -28 -26 -20 -20 -30 -32 -25
Total Pre-Tax Income 		-52 -43 -47 -34 -28 -26 -20 -20 -30 -32 -25
Total Operating Income		 -57 -49 -50 -37 -31 -27 -22 -22 -31 -34 -25
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 57 49 50 37 31 27 22 22 31 34 25
Selling, General & Admin Expense		 16 16 9.49 8.03 7.91 6.24 5.66 5.74 6.15 6.91 5.59
Research & Development Expense		 41 33 40 29 23 21 16 16 25 27 20
Total Other Income / (Expense), net		 5.50 5.49 3.17 3.64 2.73 1.37 1.65 1.81 1.19 1.14 0.57
Interest Expense		 1.79 1.87 1.94 1.91 1.91 1.06 0.94 0.91 0.87 0.60 0.15
Interest & Investment Income		 6.91 6.66 4.76 5.10 4.19 1.96 2.16 2.24 1.62 0.89 0.57
Other Income / (Expense), net		 0.39 0.70 0.34 0.44 0.45 0.47 0.44 0.48 0.44 0.85 0.15
Basic Earnings per Share		 ($0.81) ($0.72) ($0.85) ($0.62) ($0.56) ($0.54) ($0.45) ($0.46) ($0.80) ($1.18) ($0.91)
Weighted Average Basic Shares Outstanding		 63.67M 55.33M 54.90M 54.73M 50.97M 42.71M 44.36M 44.27M 37.67M 26.57M 27.22M
Diluted Earnings per Share		 ($0.81) ($0.72) ($0.85) ($0.62) ($0.56) ($0.54) ($0.45) ($0.46) ($0.80) ($1.18) ($0.91)
Weighted Average Diluted Shares Outstanding		 63.67M 55.33M 54.90M 54.73M 50.97M 42.71M 44.36M 44.27M 37.67M 26.57M 27.22M
Weighted Average Basic & Diluted Shares Outstanding		 63.77M 0.00 63.32M 54.83M 54.70M 54.45M 44.43M 44.32M 44.26M 44.26M 27.66M

Annual Cash Flow Statements for Vera Therapeutics

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents		 47 1.93 -36 26 19
Net Cash From Operating Activities		 -135 -92 -68 -24 -35
Net Cash From Continuing Operating Activities		 -135 -92 -68 -24 -66
Net Income / (Loss) Continuing Operations		 -152 -96 -89 -33 -53
Consolidated Net Income / (Loss)		 -152 -96 -89 -33 -53
Depreciation Expense		 0.11 0.02 -0.85 0.18 0.25
Amortization Expense		 -8.16 -4.11 - - -
Non-Cash Adjustments To Reconcile Net Income		 23 14 13 1.21 18
Changes in Operating Assets and Liabilities, net		 2.66 -5.82 9.35 7.51 0.12
Net Cash From Investing Activities		 -425 -39 -71 -4.20 -0.04
Net Cash From Continuing Investing Activities		 -425 -39 -71 -4.20 -0.04
Purchase of Property, Plant & Equipment		 -0.97 -0.06 -0.06 -5.00 -0.10
Purchase of Investments		 -703 -225 -148 0.00 -
Sale and/or Maturity of Investments		 279 186 78 0.00 -
Net Cash From Financing Activities		 607 134 102 54 85
Net Cash From Continuing Financing Activities		 607 134 102 54 86
Repayment of Debt		 0.00 25 - 4.92 -0.02
Repurchase of Common Equity		 -0.01 0.00 - -2.77 0.00
Issuance of Common Equity		 646 116 88 52 0.00
Other Financing Activities, net		 -39 -7.26 14 0.00 0.10
Cash Interest Paid		 6.65 3.35 0.90 0.02 0.03

Quarterly Cash Flow Statements for Vera Therapeutics

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -38 65 2.17 -44 23 18 -6.45 -104 94 13 -20
Net Cash From Operating Activities		 -54 -39 -37 -25 -34 -25 -23 -18 -26 -21 -18
Net Cash From Continuing Operating Activities		 -54 -39 -37 -25 -34 -25 -23 -18 -26 -21 -18
Net Income / (Loss) Continuing Operations		 -52 -43 -47 -34 -28 -26 -20 -20 -30 -32 -25
Consolidated Net Income / (Loss)		 -52 -43 -47 -34 -28 -26 -20 -20 -30 -32 -25
Depreciation Expense		 0.09 0.06 0.02 1.50 -1.47 0.00 0.01 0.52 -0.51 -0.60 -0.15
Amortization Expense		 -2.31 -1.85 -6.70 - - -1.17 -3.09 - - - -
Non-Cash Adjustments To Reconcile Net Income		 8.56 6.77 11 1.54 4.00 3.75 5.11 2.29 2.57 2.65 6.23
Changes in Operating Assets and Liabilities, net		 -9.04 -0.73 5.86 5.51 -7.98 -2.08 -4.90 -0.57 1.72 9.23 0.18
Net Cash From Investing Activities		 15 -221 38 -23 -219 19 16 -86 12 13 -2.44
Net Cash From Continuing Investing Activities		 15 -221 38 -23 -219 19 16 -86 12 13 -2.44
Purchase of Property, Plant & Equipment		 -0.19 -0.65 -0.24 - - -0.06 - - - - -0.04
Purchase of Investments		 -90 -294 -73 -81 -255 -53 -29 -109 -34 -11 -40
Sale and/or Maturity of Investments		 106 73 112 59 36 72 45 22 46 24 38
Other Investing Activities, net		 -0.75 - - - - - - - - - -
Net Cash From Financing Activities		 1.53 326 0.74 3.44 277 25 0.30 0.43 108 21 0.91
Net Cash From Continuing Financing Activities		 1.53 326 0.74 3.44 277 25 0.30 0.43 108 21 0.91
Repurchase of Common Equity		 0.00 - - - - - - - - - -
Issuance of Common Equity		 1.53 347 0.75 3.44 294 0.09 0.30 0.43 115 0.83 0.98
Other Financing Activities, net		 0.00 -21 - - -18 - - - -7.26 20 -0.07
Cash Interest Paid		 1.58 1.66 1.74 1.73 1.52 0.85 0.86 -1.62 3.25 0.56 0.12

Annual Balance Sheets for Vera Therapeutics

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 656 176 131 84 55
Total Current Assets		 651 172 126 83 54
Cash & Equivalents		 93 46 43 80 54
Short-Term Investments		 548 115 71 0.00 -
Prepaid Expenses		 10 11 11 2.86 0.56
Plant, Property, & Equipment, net		 0.96 0.09 0.05 0.00 0.00
Total Noncurrent Assets		 3.50 3.43 5.69 1.21 0.29
Other Noncurrent Operating Assets		 3.50 3.43 5.63 0.34 0.29
Total Liabilities & Shareholders' Equity		 656 176 131 84 55
Total Liabilities		 79 74 55 14 4.33
Total Current Liabilities		 25 22 26 7.69 2.41
Accounts Payable		 7.67 11 12 1.39 0.91
Accrued Expenses		 16 8.75 11 5.93 0.54
Other Current Liabilities		 1.48 2.44 2.65 0.38 0.96
Total Noncurrent Liabilities		 53 52 29 6.47 1.92
Long-Term Debt		 51 50 25 4.92 -
Other Noncurrent Operating Liabilities		 2.47 1.68 4.12 0.29 0.29
Total Equity & Noncontrolling Interests		 577 102 77 70 -89
Total Preferred & Common Equity		 577 102 77 70 -89
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 577 102 77 70 -89
Common Stock		 1,038 410 290 194 2.10
Retained Earnings		 -461 -309 -213 -124 -91
Accumulated Other Comprehensive Income / (Loss)		 0.39 0.25 -0.22 0.00 -

Quarterly Balance Sheets for Vera Therapeutics

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 610 369 397 419 176 195 210 131
Total Current Assets		 606 364 395 416 172 191 204 125
Cash & Equivalents		 55 27 25 69 27 34 137 30
Short-Term Investments		 535 326 359 335 132 147 60 84
Prepaid Expenses		 16 11 10 13 12 9.59 7.30 11
Plant, Property, & Equipment, net		 1.06 0.37 0.16 0.08 0.03 0.04 0.05 0.06
Total Noncurrent Assets		 3.03 4.06 2.39 2.91 3.96 4.52 5.11 6.33
Other Noncurrent Operating Assets		 3.03 4.06 2.39 2.91 3.95 4.50 5.05 6.21
Total Liabilities & Shareholders' Equity		 610 369 397 419 176 195 210 131
Total Liabilities		 75 80 69 66 52 55 52 26
Total Current Liabilities		 22 26 18 15 25 27 24 16
Accounts Payable		 9.26 4.60 4.66 5.21 12 13 5.33 7.01
Accrued Expenses		 11 20 12 7.06 9.80 11 16 6.22
Other Current Liabilities		 1.19 1.87 2.12 2.28 2.52 2.56 2.60 2.69
Total Noncurrent Liabilities		 53 53 51 51 27 28 28 9.73
Long-Term Debt		 51 50 50 50 25 25 25 4.97
Other Noncurrent Operating Liabilities		 2.37 2.57 0.74 1.21 2.25 2.86 3.48 4.77
Total Equity & Noncontrolling Interests		 535 289 328 354 124 141 158 106
Total Preferred & Common Equity		 535 289 328 354 124 141 158 106
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 535 289 328 354 124 141 158 106
Common Stock		 1,047 706 700 691 407 404 401 287
Retained Earnings		 -513 -418 -371 -337 -283 -263 -243 -181
Accumulated Other Comprehensive Income / (Loss)		 0.65 1.04 -0.45 -0.17 -0.08 -0.14 -0.00 -0.28

Annual Metrics And Ratios for Vera Therapeutics

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -66.20% -15.01% -179.58% 38.82% 0.00%
EBIT Growth		 -64.93% -11.55% -175.47% 38.78% 0.00%
NOPAT Growth		 -63.87% -12.22% -164.24% 34.15% 0.00%
Net Income Growth		 -58.50% -7.79% -173.10% 38.95% 0.00%
EPS Growth		 -22.22% 32.84% -37.86% 98.54% 0.00%
Operating Cash Flow Growth		 -46.10% -36.37% -185.12% 31.89% 0.00%
Free Cash Flow Firm Growth		 -50.39% -32.79% -163.17% 0.00% 0.00%
Invested Capital Growth		 -42.12% 29.55% -115.62% -73.36% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -17.38% 2.50% -22.30% 45.16% 0.00%
EBIT Q/Q Growth		 -15.08% 5.81% -21.51% 44.39% 0.00%
NOPAT Q/Q Growth		 -15.06% 6.04% -23.00% 43.02% 0.00%
Net Income Q/Q Growth		 -13.22% 6.60% -21.22% 44.39% 0.00%
EPS Q/Q Growth		 -7.00% 22.15% -140.26% 98.35% 0.00%
Operating Cash Flow Q/Q Growth		 -11.64% -4.51% -27.85% 46.91% 0.00%
Free Cash Flow Firm Q/Q Growth		 -14.17% -9.61% -14.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 5.59% 18.29% -236.78% -229.65% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 92.08% 95.81% 99.16% 100.02% 100.30%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -44.83% -107.50% -121.58% -54.43% -106.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -44.82% -107.45% -121.55% 8.97% 189.16%
Return on Equity Simple (ROE_SIMPLE)		 -26.36% -94.40% -115.80% -46.86% 59.78%
Net Operating Profit after Tax (NOPAT)		 -117 -71 -64 -24 -37
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -10.02% -24.49% -30.72% -13.19% -31.37%
Return On Investment Capital (ROIC_SIMPLE)		 -18.64% -47.12% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -165 -100 -90 -33 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -173 -104 -91 -32 -53
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 4.64 6.72 6.96 8.17 0.00
Price to Tangible Book Value (P/TBV)		 4.64 6.72 6.96 8.17 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.09 0.49 0.32 0.07 0.00
Long-Term Debt to Equity		 0.09 0.49 0.32 0.07 0.00
Financial Leverage		 -1.03 -1.12 -1.13 -1.08 -1.07
Leverage Ratio		 1.22 1.72 1.47 1.15 1.09
Compound Leverage Factor		 1.13 1.65 1.46 1.15 1.09
Debt to Total Capital		 8.07% 32.91% 24.39% 6.61% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 8.07% 32.91% 24.39% 6.61% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 277.88%
Common Equity to Total Capital		 91.93% 67.06% 75.58% 93.39% -177.88%
Debt to EBITDA		 -0.29 -0.48 -0.27 -0.15 0.00
Net Debt to EBITDA		 3.41 1.06 0.99 2.33 0.00
Long-Term Debt to EBITDA		 -0.29 -0.48 -0.27 -0.15 0.00
Debt to NOPAT		 -0.43 -0.70 -0.39 -0.20 0.00
Net Debt to NOPAT		 5.04 1.55 1.41 3.14 0.00
Long-Term Debt to NOPAT		 -0.43 -0.70 -0.39 -0.20 0.00
Altman Z-Score		 19.79 2.23 2.28 21.81 2.21
Noncontrolling Interest Sharing Ratio		 0.01% 0.04% 0.02% 116.49% 277.88%
Liquidity Ratios		 - - - - -
Current Ratio		 25.67 7.71 4.91 10.73 22.55
Quick Ratio		 25.26 7.21 4.48 10.36 22.30
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 -113 -75 -57 -22 0.00
Operating Cash Flow to CapEx		 -13,855.86% -146,319.05% -109,025.81% -474.16% -82,878.57%
Free Cash Flow to Firm to Interest Expense		 -14.84 -19.88 -57.12 -1,076.57 0.00
Operating Cash Flow to Interest Expense		 -17.66 -24.35 -68.14 -1,185.40 -209.69
Operating Cash Flow Less CapEx to Interest Expense		 -17.79 -24.36 -68.20 -1,435.40 -209.95
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -13 -9.15 -13 -6.03 -3.48
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.86 3.84 -6.97 -2.55 0.00
Enterprise Value (EV)		 2,088 573 445 493 134
Market Capitalization		 2,678 683 535 569 48
Book Value per Share		 $9.11 $2.29 $2.78 $3.27 ($279.24)
Tangible Book Value per Share		 $9.11 $2.29 $2.78 $3.27 ($279.24)
Total Capital		 628 152 102 75 50
Total Debt		 51 50 25 4.92 0.00
Total Long-Term Debt		 51 50 25 4.92 0.00
Net Debt		 -590 -111 -90 -76 -54
Capital Expenditures (CapEx)		 0.97 0.06 0.06 5.00 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -11 -15 -4.83 -1.85
Debt-free Net Working Capital (DFNWC)		 626 150 100 75 52
Net Working Capital (NWC)		 626 150 100 75 52
Net Nonoperating Expense (NNE)		 35 25 25 8.53 17
Net Nonoperating Obligations (NNO)		 -590 -111 -90 -76 -54
Total Depreciation and Amortization (D&A)		 -8.06 -4.09 -0.85 0.18 0.25
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 ($2.75) ($2.25) ($3.35) ($2.43) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 55.33M 42.71M 26.57M 27.05M 0.00
Adjusted Diluted Earnings per Share		 ($2.75) ($2.25) ($3.35) ($2.43) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 55.33M 42.71M 26.57M 27.05M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.43) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 54.45M 44.26M 13.44M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -117 -71 -64 -24 -34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -21.67 -26.46 -90.54 -1,630.15 -320.81
NOPAT to Interest Expense		 -15.34 -18.86 -64.15 -1,204.07 -220.29
EBIT Less CapEx to Interest Expense		 -21.79 -26.48 -90.60 -1,880.15 -321.06
NOPAT Less CapEx to Interest Expense		 -15.47 -18.88 -64.21 -1,454.07 -220.55
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.01% 0.00% 0.00% -8.48% 0.00%

Quarterly Metrics And Ratios for Vera Therapeutics

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -83.72% -80.38% -130.03% -68.84% -2.58% 16.82% 3.36% -38.93% -84.43% -98.39% -234.14%
EBIT Growth		 -85.27% -81.55% -131.99% -71.73% 0.50% 18.86% 15.06% -43.36% -81.36% -94.47% -229.56%
NOPAT Growth		 -83.83% -80.98% -128.91% -69.97% 0.47% 19.51% 13.82% -45.91% -83.64% -102.48% -248.10%
Net Income Growth		 -82.13% -69.27% -131.95% -67.19% 5.61% 20.91% 18.54% -35.74% -76.00% -92.55% -224.25%
EPS Growth		 -44.64% -33.33% -88.89% -34.78% 30.00% 54.24% 50.55% 16.36% -12.68% -111.25% -152.78%
Operating Cash Flow Growth		 -60.82% -55.83% -60.56% -39.44% -28.67% -18.82% -24.72% 6.63% -192.75% -228.70% -235.89%
Free Cash Flow Firm Growth		 0.48% -33.50% -309.46% -531.91% -87.10% -37.60% 49.59% 2.30% -536.00% -82.57% -381.49%
Invested Capital Growth		 -6,912.50% -42.12% -23.01% 59.81% 99.62% 29.55% -190.38% -168.55% -20.23% -115.62% -111.05%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -18.04% 10.91% -58.54% -10.19% -15.90% -13.62% -16.37% 33.05% 6.02% -31.99% -67.29%
EBIT Q/Q Growth		 -17.82% 2.51% -34.03% -20.34% -15.46% -24.57% 0.78% 30.28% 5.85% -30.42% -67.46%
NOPAT Q/Q Growth		 -16.93% 1.78% -33.36% -20.03% -15.11% -24.23% 0.97% 29.71% 6.92% -33.03% -67.66%
Net Income Q/Q Growth		 -19.04% 6.88% -38.34% -18.76% -10.63% -27.61% 0.29% 32.95% 7.31% -31.44% -66.16%
EPS Q/Q Growth		 -12.50% 15.29% -37.10% -10.71% -3.70% -20.00% 2.17% 42.50% 32.20% -29.67% -65.45%
Operating Cash Flow Q/Q Growth		 -38.85% -6.23% -48.84% 26.75% -34.55% -9.45% -29.27% 32.41% -24.24% -14.89% 3.22%
Free Cash Flow Firm Q/Q Growth		 -19.03% 5.88% 8.93% 2.44% -59.66% -188.66% -40.54% 71.11% -17.42% -5.75% -172.40%
Invested Capital Q/Q Growth		 69.82% 5.59% -120.32% -11,069.64% 99.39% 18.29% 28.02% -6.50% -12.48% -236.78% 33.44%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.00% 90.06% 94.29% 91.35% 92.56% 96.60% 94.30% 93.83% 97.57% 99.10% 98.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -39.49% -44.83% -65.11% -46.05% -36.89% -107.50% -89.59% -81.94% -69.86% -121.58% -76.85%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -39.49% -44.82% -65.10% -46.05% -36.89% -107.45% -89.59% -81.94% -69.85% -121.55% -76.85%
Return on Equity Simple (ROE_SIMPLE)		 -32.80% 0.00% -46.49% -32.89% -26.67% 0.00% -83.08% -76.39% -64.70% 0.00% -69.49%
Net Operating Profit after Tax (NOPAT)		 -40 -34 -35 -26 -22 -19 -15 -15 -22 -24 -18
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.61% -2.62% -5.38% -3.09% -2.51% -6.71% -3.99% -3.38% -5.14% -10.79% -7.12%
Return On Investment Capital (ROIC_SIMPLE)		 -6.83% -5.45% - - - -12.48% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -57 -48 -49 -37 -31 -27 -21 -21 -31 -33 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -59 -50 -56 -35 -32 -28 -24 -21 -31 -33 -25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.86 4.64 8.39 6.04 6.64 6.72 4.91 5.06 2.18 6.96 5.47
Price to Tangible Book Value (P/TBV)		 2.86 4.64 8.39 6.04 6.64 6.72 4.91 5.06 2.18 6.96 5.47
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.10 0.09 0.17 0.15 0.14 0.49 0.20 0.18 0.16 0.32 0.05
Long-Term Debt to Equity		 0.10 0.09 0.17 0.15 0.14 0.49 0.20 0.18 0.16 0.32 0.05
Financial Leverage		 -1.00 -1.03 -1.06 -1.05 -1.03 -1.12 -1.07 -1.08 -1.09 -1.13 -1.03
Leverage Ratio		 1.16 1.22 1.32 1.26 1.23 1.72 1.34 1.31 1.28 1.47 1.16
Compound Leverage Factor		 1.05 1.10 1.24 1.16 1.14 1.66 1.26 1.23 1.25 1.46 1.14
Debt to Total Capital		 8.69% 8.07% 14.86% 13.29% 12.40% 32.91% 16.84% 15.08% 13.63% 24.39% 4.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 8.69% 8.07% 14.86% 13.29% 12.40% 32.91% 16.84% 15.08% 13.63% 24.39% 4.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.31% 91.93% 85.12% 86.71% 87.60% 67.06% 83.16% 84.92% 86.37% 75.58% 95.51%
Debt to EBITDA		 -0.25 -0.29 -0.34 -0.42 -0.48 -0.48 -0.23 -0.23 -0.24 -0.27 -0.07
Net Debt to EBITDA		 2.69 3.41 2.05 2.80 3.37 1.06 1.26 1.41 1.64 0.99 1.48
Long-Term Debt to EBITDA		 -0.25 -0.29 -0.34 -0.42 -0.48 -0.48 -0.23 -0.23 -0.24 -0.27 -0.07
Debt to NOPAT		 -0.38 -0.43 -0.50 -0.61 -0.70 -0.70 -0.33 -0.32 -0.34 -0.39 -0.10
Net Debt to NOPAT		 3.98 5.04 2.98 4.07 4.96 1.55 1.78 1.99 2.34 1.41 2.12
Long-Term Debt to NOPAT		 -0.38 -0.43 -0.50 -0.61 -0.70 -0.70 -0.33 -0.32 -0.34 -0.39 -0.10
Altman Z-Score		 11.89 20.38 17.36 16.63 21.19 3.61 5.37 6.55 2.90 3.71 11.97
Noncontrolling Interest Sharing Ratio		 0.00% 0.01% 0.01% 0.00% 0.00% 0.04% 0.00% 0.00% 0.01% 0.02% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 27.68 25.67 13.76 21.43 28.63 7.71 6.97 7.10 8.69 4.91 7.85
Quick Ratio		 26.94 25.26 13.35 20.87 27.76 7.21 6.50 6.75 8.38 4.48 7.19
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -30 -32 -35 -36 -23 -7.88 -5.61 -19 -17 -16
Operating Cash Flow to CapEx		 -29,094.12% -6,074.73% -15,497.90% 0.00% 0.00% -39,911.11% 0.00% 0.00% 0.00% 0.00% -48,473.68%
Free Cash Flow to Firm to Interest Expense		 -20.18 -16.23 -16.67 -18.54 -19.06 -21.57 -8.36 -6.14 -22.22 -27.61 -106.40
Operating Cash Flow to Interest Expense		 -30.36 -20.93 -19.05 -12.96 -17.75 -23.83 -24.36 -19.44 -30.08 -35.33 -125.31
Operating Cash Flow Less CapEx to Interest Expense		 -30.46 -21.28 -19.18 -12.96 -17.75 -23.89 -24.36 -19.44 -30.08 -35.33 -125.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.93 -13 -14 -6.26 -0.06 -9.15 -11 -16 -15 -13 -3.86
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.87 -3.86 -2.58 9.31 15 3.84 -7.35 -9.77 -2.46 -6.97 -2.03
Enterprise Value (EV)		 992 2,088 2,121 1,645 1,994 573 473 554 171 445 469
Market Capitalization		 1,531 2,678 2,423 1,979 2,348 683 608 710 343 535 578
Book Value per Share		 $8.39 $9.11 $5.27 $5.99 $6.49 $2.29 $2.79 $3.17 $3.56 $2.78 $3.90
Tangible Book Value per Share		 $8.39 $9.11 $5.27 $5.99 $6.49 $2.29 $2.79 $3.17 $3.56 $2.78 $3.90
Total Capital		 586 628 340 378 404 152 149 165 183 102 111
Total Debt		 51 51 50 50 50 50 25 25 25 25 4.97
Total Long-Term Debt		 51 51 50 50 50 50 25 25 25 25 4.97
Net Debt		 -539 -590 -303 -334 -354 -111 -135 -156 -172 -90 -110
Capital Expenditures (CapEx)		 0.19 0.65 0.24 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.65 -15 -16 -8.06 -1.84 -11 -13 -17 -16 -15 -5.36
Debt-free Net Working Capital (DFNWC)		 584 626 338 376 402 150 147 164 181 100 109
Net Working Capital (NWC)		 584 626 338 376 402 150 147 164 181 100 109
Net Nonoperating Expense (NNE)		 12 9.19 12 7.57 6.60 6.74 4.87 4.78 8.19 8.93 7.01
Net Nonoperating Obligations (NNO)		 -539 -590 -303 -334 -354 -111 -135 -156 -172 -90 -110
Total Depreciation and Amortization (D&A)		 -2.23 -1.79 -6.68 1.50 -1.47 -1.17 -3.08 0.52 -0.51 -0.60 -0.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.81) ($0.72) ($0.85) ($0.62) ($0.56) ($0.54) ($0.45) ($0.46) ($0.80) ($1.18) ($0.91)
Adjusted Weighted Average Basic Shares Outstanding		 63.67M 55.33M 54.90M 54.73M 50.97M 42.71M 44.36M 44.27M 37.67M 26.57M 27.22M
Adjusted Diluted Earnings per Share		 ($0.81) ($0.72) ($0.85) ($0.62) ($0.56) ($0.54) ($0.45) ($0.46) ($0.80) ($1.18) ($0.91)
Adjusted Weighted Average Diluted Shares Outstanding		 63.67M 55.33M 54.90M 54.73M 50.97M 42.71M 44.36M 44.27M 37.67M 26.57M 27.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 63.77M 0.00 63.32M 54.83M 54.70M 54.45M 44.43M 44.32M 44.26M 44.26M 27.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -40 -34 -35 -26 -22 -19 -15 -15 -22 -24 -18
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -31.70 -25.76 -25.55 -19.30 -16.09 -25.17 -22.61 -23.51 -35.26 -54.65 -170.74
NOPAT to Interest Expense		 -22.34 -18.29 -18.01 -13.67 -11.43 -17.93 -16.15 -16.83 -25.04 -39.24 -120.21
EBIT Less CapEx to Interest Expense		 -31.81 -26.10 -25.67 -19.30 -16.09 -25.23 -22.61 -23.51 -35.26 -54.65 -171.00
NOPAT Less CapEx to Interest Expense		 -22.45 -18.64 -18.13 -13.67 -11.43 -17.99 -16.15 -16.83 -25.04 -39.24 -120.47
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.01% -0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Vera Therapeutics' Financials

When does Vera Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Vera Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Vera Therapeutics' net income changed over the last 4 years?

Vera Therapeutics' net income appears to be on an upward trend, with a most recent value of -$152.15 million in 2024, rising from -$53.41 million in 2020. The previous period was -$95.99 million in 2023. Check out Vera Therapeutics' forecast to explore projected trends and price targets.

What is Vera Therapeutics's operating income?
Vera Therapeutics's total operating income in 2024 was -$167.17 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $167.17 million
How has Vera Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Vera Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Vera Therapeutics have?

Vera Therapeutics' total liabilities were at $78.53 million at the end of 2024, a 6.3% increase from 2023, and a 1,715.2% increase since 2020.

How much cash does Vera Therapeutics have?

In the past 4 years, Vera Therapeutics' cash and equivalents has ranged from $43.46 million in 2022 to $92.65 million in 2024, and is currently $92.65 million as of their latest financial filing in 2024.

How has Vera Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Vera Therapeutics' book value per share changed from -279.24 in 2020 to 9.11 in 2024, a change of -103.3%.


Related Companies

This page (NASDAQ:VERA) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored